Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed K. Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean‐Charles Soria, Gypsyamber DʼSouza
Abstract
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
Topics & Concepts
VaccinationCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCancerMedicineOutbreakInternal medicineDiseaseInfectious disease (medical specialty)COVID-19 and healthcare impactsHealthcare cost, quality, practicesCOVID-19 Clinical Research Studies